91524-96-8

Basic information

• Product Name: 2-chlorothiazolo[5,4-b]pyridine
• Synonyms: 2-chlorothiazolo[5,4-b]pyridine
• CAS NO: 91524-96-8
• Molecular Formula: C₆H₃ClN₂S
• Molecular Weight: 170.61942
• Mol File: 91524-96-8.mol

Chemical Properties

• Boiling Point: 263.5±13.0 °C(Predicted)
• Appearance: /
• Density: 1.531±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 0.17±0.50(Predicted)
• CAS DataBase Reference: 2-chlorothiazolo[5,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chlorothiazolo[5,4-b]pyridine(91524-96-8)
• EPA Substance Registry System: 2-chlorothiazolo[5,4-b]pyridine(91524-96-8)

Safety Data

• Hazardous Substances Data: 91524-96-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-chlorothiazolo[5,4-b]pyridine is utilized as a key building block for the synthesis of new drug candidates due to its unique chemical structure and potential biological activities.
Used in Antimicrobial and Antiviral Applications:
In the field of infectious diseases, 2-chlorothiazolo[5,4-b]pyridine is studied as a potential antimicrobial and antiviral agent, highlighting its use in combating various pathogens and viruses.
Used in Neurological Disorder Treatment:
2-chlorothiazolo[5,4-b]pyridine is explored for its potential role in the treatment of neurological disorders, indicating its possible application in managing conditions affecting the brain and nervous system.
Used in Cancer and Disease Treatment Research:
As an inhibitor of protein kinase C, 2-chlorothiazolo[5,4-b]pyridine is investigated for its implications in the treatment of cancer and other diseases, suggesting its use in modulating cellular signaling pathways related to these conditions.
Overall, 2-chlorothiazolo[5,4-b]pyridine's diverse applications in medical research underscore its potential as a valuable compound in the development of novel therapeutics across multiple health disciplines.

Upstream product

• 39856-58-1 3-amino-2-bromopyridine 
• 140-89-6 potassium ethyl xanthogenate 
• 57135-09-8 1H,2H-[1,3]thiazolo[5,4-b]pyridine-2-thione 

Downstream Products

• 67219-30-1 2,2,2-trifluoro-N-thiazolo[5,4-b]pyridin-2-yl-acetamide 
• 1206541-22-1 C₂₁H₁₉N₃O₂S 
• 1190927-42-4 [4-([1,3]thiazolo[5,4-b]pyridin-2-yloxy)phenyl]methanol 
• 60419-63-8 thiazolo[5,4-b]pyridin-2-yl-malonic acid diethyl ester 
• 60419-66-1 thiazolo[5,4-b]pyridin-2-yl-malononitrile 
• 67219-27-6 2-methoxy-thiazolo[5,4-b]pyridine 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY

This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.